Update shared on20 Aug 2025
Fair value Increased 101%The notable increase in Oncopeptides' fair value target is primarily driven by a higher forecasted future P/E multiple, despite a marginal dip in revenue growth expectations, with the analyst consensus price target rising from SEK2.73 to SEK3.25.
What's in the News
- Strategic partnership with SD Pharma enhances Pepaxti's hospital reach in Spain without upfront costs, starting Q3 2025.
- Two real-world evidence posters on Pepaxti outcomes in multiple myeloma accepted for presentation at IMS Annual Meeting, highlighting increased clinical use and physician interest.
- Guidance issued for Q2 2025 net sales of SEK 19.2 million and H1 2025 sales of SEK 32.5 million, up from SEK 8.2 million and SEK 13.2 million in the prior-year periods.
- Pepaxti included in new EHA-EMN clinical guidelines for relapsed/refractory multiple myeloma, recommended with Level 1 evidence and Grade B for triple-class and quadruple-class refractory patients.
Valuation Changes
Summary of Valuation Changes for Oncopeptides
- The Consensus Analyst Price Target has significantly risen from SEK2.73 to SEK3.25.
- The Future P/E for Oncopeptides has significantly risen from 8.87x to 11.14x.
- The Consensus Revenue Growth forecasts for Oncopeptides has fallen slightly from 121.7% per annum to 117.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.